Condition 1: Ischemic cardiomyopathy. Condition 2: Dilated cardiomyopathy. Ischemic cardiomyopathy Dilated cardiomyopathy
Conditions
Interventions
Intervention 1: Intervention group: Sacubitril valsartan (under the brand name: Artrestan, Arena Hayat co) with the starting dose of 50mg twice daily will be prescribed to patients with any degree of
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: patients who aged over 18 years old patients with any degree of right ventricular failure written and informed consent
Exclusion criteria
Exclusion criteria: glomerular filteration rate less than 30 mg/dl systolic blood pressure less than 100 mmHg history of angioedema right heart failure due to acute pulmonary emboli creatinine more than 2.5mg/dl renal artery stenosis hisory of intolerance to the mentioned drugs Death Lack of consent to prticipate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of RV dysfunction. Timepoint: At the beginning of the trial, 3 months after using the drug. Method of measurement: Echocardiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZeinali, Elahe
Iran University of Medical Sciences
Outcome results
None listed